Aligos Therapeutics (NASDAQ:ALGS) Announces Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Aligos Therapeutics (NASDAQ:ALGS) posted its quarterly earnings results on Tuesday. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.16) by $0.19, Zacks reports. Aligos Therapeutics had a negative net margin of 783.72% and a negative return on equity of 144.16%. The firm had revenue of $1.06 million for the quarter. During the same quarter in the previous year, the business posted ($0.43) EPS.

Aligos Therapeutics Price Performance

NASDAQ ALGS traded up $0.02 during mid-day trading on Friday, hitting $0.56. The company’s stock had a trading volume of 210,916 shares, compared to its average volume of 374,917. Aligos Therapeutics has a 52-week low of $0.35 and a 52-week high of $1.20. The stock’s fifty day simple moving average is $0.49 and its two-hundred day simple moving average is $0.70. The firm has a market capitalization of $43.91 million, a P/E ratio of -0.44 and a beta of 2.18.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).